Deep clinical and biological phenotyping of the preterm birth and small for gestational age syndromes: The INTERBIO-21st Newborn Case-Control Study protocol
Kennedy SH., Victora CG., Craik R., Ash S., Barros FC., Barsosio HC., Berkley JA., Carvalho M., Fernandes M., Cheikh Ismail L., Lambert A., Lindgren CM., McGready R., Munim S., Nellåker C., Noble JA., Norris SA., Nosten F., Ohuma EO., Papageorghiou AT., Stein A., Stones W., Tshivuila-Matala COO., Staines Urias E., Vatish M., Wulff K., Zainab G., Zondervan KT., Uauy R., Bhutta ZA., Villar J.
<ns4:p><ns4:bold>Background:</ns4:bold> INTERBIO-21<ns4:sup>st</ns4:sup> is Phase II of the INTERGROWTH-21<ns4:sup>st</ns4:sup> Project, the population-based, research initiative involving nearly 70,000 mothers and babies worldwide coordinated by Oxford University and performed by a multidisciplinary network of more than 400 healthcare professionals and scientists from 35 institutions in 21 countries worldwide. Phase I, conducted 2008-2015, consisted of nine complementary studies designed to describe optimal human growth and neurodevelopment, based conceptually on the WHO prescriptive approach. The studies generated a set of international standards for monitoring growth and neurodevelopment, which complement the existing WHO Child Growth Standards. Phase II aims to improve the functional classification of the highly heterogenous preterm birth and fetal growth restriction syndromes through a better understanding of how environmental exposures, clinical conditions and nutrition influence patterns of human growth from conception to childhood, as well as specific neurodevelopmental domains and associated behaviors at 2 years of age.</ns4:p><ns4:p> <ns4:bold>Methods:</ns4:bold> In the INTERBIO-21<ns4:sup>st</ns4:sup> Newborn Case-Control Study, a major component of Phase II, our objective is to investigate the mechanisms potentially responsible for preterm birth and small for gestational age and their interactions, using deep phenotyping of clinical, growth and epidemiological data and associated nutritional, biochemical, omic and histological profiles. Here we describe the study sites, population characteristics, study design, methodology and standardization procedures for the collection of longitudinal clinical data and biological samples (maternal blood, umbilical cord blood, placental tissue, maternal feces and infant buccal swabs) for the study that was conducted between 2012 and 2018 in Brazil, Kenya, Pakistan, South Africa, Thailand and the UK.</ns4:p><ns4:p> <ns4:bold>Discussion:</ns4:bold> Our study provides a unique resource for the planned analyses given the range of potentially disadvantageous exposures (including poor nutrition, pregnancy complications and infections) in geographically diverse populations worldwide. The study should enhance current medical knowledge and provide new insights into environmental influences on human growth and neurodevelopment.</ns4:p>